AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 394280 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (25 mg, three times daily for the first week, then four or six tablets in the second week)
Number of subjects: 44
Study 394280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 394280 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 44
Study 394280 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac and Placebo
Number of subjects: 44
Study 31452437 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene signature model (including T stage, N stage, HPV status, and gene signature)
Number of subjects: 262
Study 31452437 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene signature model
Number of subjects: 262
Study 27628045 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol 60,000 units 4 weekly (group 1)
Number of subjects: 52
Study 27628045 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol 60,000 units 8 weekly (group 2)
Number of subjects: 52
Study 27628045 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 3)
Number of subjects: 52
Study 26493478 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet and exercise program (8-week program)
Number of subjects: 20
Study 26493478 — intervention group
Group type: COMPARATOR
Intervention: Control group (Mediterranean diet education only)
Number of subjects: 20
Study 26493478 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Mediterranean diet education)
Number of subjects: 20
Study 23534003 — intervention group
Group type: EXPERIMENTAL
Intervention: etch‐and‐rinse/rubber‐dam (ERR)
Number of subjects: 38
Study 23534003 — intervention group
Group type: EXPERIMENTAL
Intervention: etch‐and‐rinse/cotton roll (ERC)
Number of subjects: 38
Study 23534003 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐etching/rubber‐dam (SER)
Number of subjects: 38
Study 23534003 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐etching/cotton roll (SEC)
Number of subjects: 38
Study 23534003 — intervention group
Group type: EXPERIMENTAL
Intervention: rubber‐dam isolation
Number of subjects: 38
Study 23534003 — intervention group
Group type: COMPARATOR
Intervention: cotton roll isolation
Number of subjects: 38
Study 21896760 — intervention group
Group type: EXPERIMENTAL
Intervention: Social condition (observing the outcome of the lottery chosen by another person)
Number of subjects: 0
Study 21896760 — intervention group
Group type: COMPARATOR
Intervention: Private condition (observing the outcome of the unchosen lottery)
Number of subjects: 0
Study 21896760 — intervention group
Group type: EXPERIMENTAL
Intervention: Social gains
Number of subjects: 0
Study 19264972 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondhand smoke (SHS) exposure for 1 hour
Number of subjects: 16
Study 17395358 — intervention group
Group type: EXPERIMENTAL
Intervention: AED/CPR training and possession of the device
Number of subjects: 158
Study 17395358 — intervention group
Group type: COMPARATOR
Intervention: CPR training
Number of subjects: 158
Study 15154938 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 2 g/day for 4 weeks
Number of subjects: 75
Study 15154938 — intervention group
Group type: COMPARATOR
Intervention: No anti-oxidant for 4 weeks
Number of subjects: 75
Study 12057137 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation given concurrently with chemotherapy followed by three courses of combination chemotherapy
Number of subjects: 100
Study 12057137 — intervention group
Group type: COMPARATOR
Intervention: Conventional course of radiation
Number of subjects: 100
Study 9258852 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 maximum voluntary eccentric contractions
Number of subjects: 24
Study 9258852 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 maximum voluntary eccentric contractions
Number of subjects: 24
Study 9258852 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 maximum voluntary eccentric contractions
Number of subjects: 24
Study 9258852 — intervention group
Group type: EXPERIMENTAL
Intervention: Second bout of 50 contractions
Number of subjects: 24
Study 8490338 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy and ventilation tubes (grommets)
Number of subjects: 228
Study 8490338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation tubes (grommets) alone
Number of subjects: 228
Study 8490338 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy alone
Number of subjects: 228
Study 8490338 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of adenoidectomy and ventilation tubes
Number of subjects: 228
Study 8490338 — intervention group
Group type: COMPARATOR
Intervention: No surgery
Number of subjects: 228
Study 3688382 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidisic (jelly artificial tear solution)
Number of subjects: 40
Study 3688382 — intervention group
Group type: COMPARATOR
Intervention: Dexpanthenol ointment
Number of subjects: 40
Study 31733345 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU)
Number of subjects: 25871
Study 29813159 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxies estimating survival less than 6 months
Number of subjects: 764
Study 29813159 — intervention group
Group type: COMPARATOR
Intervention: Proxies estimating survival greater than 6 months
Number of subjects: 764
Study 29813159 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxies perceiving resident would die within 6 months
Number of subjects: 764
Study 27280792 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-Amodiaquine (ASAQ)
Number of subjects: 865
Study 24680615 — intervention group
Group type: EXPERIMENTAL
Intervention: Lindioil (experimental group)
Number of subjects: 31
Study 24680615 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control group)
Number of subjects: 31
Study 22971559 — intervention group
Group type: EXPERIMENTAL
Intervention: LMS-PA (LMS-oriented lesson plans)
Number of subjects: 8
Study 22971559 — intervention group
Group type: COMPARATOR
Intervention: Control group (supervised free playtime)
Number of subjects: 8
Study 20855114 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg RBZ at baseline and months 1, 3, and 5 (group 1)
Number of subjects: 126
Study 20855114 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal or grid laser photocoagulation at baseline and month 3 if needed (group 2)
Number of subjects: 126
Study 20855114 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.5 mg RBZ and focal or grid laser at baseline and month 3 (group 3)
Number of subjects: 126
Study 18668535 — intervention group
Group type: EXPERIMENTAL
Intervention: rilonacept (160 mg weekly subcutaneous injections)
Number of subjects: 47
Study 18668535 — intervention group
Group type: EXPERIMENTAL
Intervention: rilonacept
Number of subjects: 47
Study 18668535 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 47
Study 15922530 — intervention group
Group type: EXPERIMENTAL
Intervention: Cozart amphetamine ELISA screening assay
Number of subjects: 360
Study 15922530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 12008860 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's Wort (Hypericum perforatum) extract (Calmigen)
Number of subjects: 70
Study 12008860 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine hydrochloride (Prozac)
Number of subjects: 70
Study 10360845 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol bolus dose of 2 mg/kg or 1 mg/kg for those older than 65 years, followed by infusion of 25, 50, 100, or 200 microg x kg(‐1) x min(‐1) of propofol.
Number of subjects: 24
Study 7655194 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stitch technique
Number of subjects: 200
Study 7655194 — intervention group
Group type: COMPARATOR
Intervention: No-stitch technique
Number of subjects: 200
Study 1778191 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release verapamil (SRV) 360 mg
Number of subjects: 30
Study 1778191 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 30
Study 6212450 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographical localization of the porta hepatis prior to PTC
Number of subjects: 64
Study 6212450 — intervention group
Group type: COMPARATOR
Intervention: Fine needle PTC without prior ultrasonographical localization
Number of subjects: 64
Study 30807432 — intervention group
Group type: EXPERIMENTAL
Intervention: Peezy midstream collection device with castile soap wipe
Number of subjects: 62
Study 30807432 — intervention group
Group type: EXPERIMENTAL
Intervention: Peezy midstream collection device without castile soap wipe
Number of subjects: 62
Study 30807432 — intervention group
Group type: COMPARATOR
Intervention: Standard clean catch midstream urine protocol
Number of subjects: 62
Study 28882742 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative news headlines
Number of subjects: 2056
Study 28882742 — intervention group
Group type: EXPERIMENTAL
Intervention: Conflicting news headlines
Number of subjects: 2056
Study 28882742 — intervention group
Group type: COMPARATOR
Intervention: Positive news headlines
Number of subjects: 2056
Study 28882742 — intervention group
Group type: COMPARATOR
Intervention: No-message
Number of subjects: 2056
Study 26115560 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean diet
Number of subjects: 31
Study 24512053 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofogliflozin 20 mg once daily for 52 weeks
Number of subjects: 796
Study 24512053 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofogliflozin 40 mg once daily for 52 weeks
Number of subjects: 796
Study 24512053 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofogliflozin (doses not specified) in add-on trial
Number of subjects: 796
Study 23216439 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use treatment for AAPIs
Number of subjects: 298
Study 23216439 — intervention group
Group type: COMPARATOR
Intervention: Substance use treatment for non-AAPIs (control group)
Number of subjects: 298
Study 19081092 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g L-arginine added to a fatty meal (3 ml cream/kg body weight)
Number of subjects: 15
Study 19081092 — intervention group
Group type: COMPARATOR
Intervention: Fatty meal without L-arginine
Number of subjects: 15
Study 19081092 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g phenylalanine added to a fatty meal
Number of subjects: 15
Study 19081092 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g leucine added to a fatty meal
Number of subjects: 15
Study 19081092 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g L-arginine alone (without cream)
Number of subjects: 15
Study 17560290 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (ENOX)
Number of subjects: 15191
Study 17560290 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 15191
Study 15505128 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC diet
Number of subjects: 60
Study 15505128 — intervention group
Group type: COMPARATOR
Intervention: NCEP diet
Number of subjects: 60
Study 11506764 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal methods (Generalized Estimating Equations and Generalized Linear Mixed Models)
Number of subjects: 0
Study 11506764 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-naïve methods (tests of proportions and logistic regression)
Number of subjects: 0
Study 11506764 — intervention group
Group type: EXPERIMENTAL
Intervention: Missing data strategies
Number of subjects: 0
Study 9924223 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% mepivacaine
Number of subjects: 10
Study 9924223 — intervention group
Group type: COMPARATOR
Intervention: 0.33% bupivacaine
Number of subjects: 10
Study 8044193 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 29
Study 8044193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 3067950 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control using ultralente insulin as basal cover and soluble insulin at mealtimes
Number of subjects: 38
Study 3067950 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin treatment
Number of subjects: 38
Study 3067950 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment
Number of subjects: 38
Study 3067950 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 38
Study 3067950 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Intensive and Conventional)
Number of subjects: 38
Study 29329551 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniscalpel acupuncture treatment
Number of subjects: 36
Study 29329551 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs (zaltoprofen, one oral tablet, three times a day for three weeks)
Number of subjects: 36
Study 29329551 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniscalpel acupuncture treatment combined with NSAIDs
Number of subjects: 36
Study 29329551 — intervention group
Group type: COMPARATOR
Intervention: Control group (NSAIDs only)
Number of subjects: 36
Study 28718535 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniectomy with full dural flap opening (Group A)
Number of subjects: 59
Study 28718535 — intervention group
Group type: COMPARATOR
Intervention: Craniectomy with multidural-slits (Group B)
Number of subjects: 59
Study 23920214 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer attached to the distal end of the Acapella
Number of subjects: 10
Study 23920214 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer placed between the mouthpiece and the Acapella
Number of subjects: 10
Study 23920214 — intervention group
Group type: COMPARATOR
Intervention: Nebulizer alone (control)
Number of subjects: 10
Study 22776014 — intervention group
Group type: EXPERIMENTAL
Intervention: Teneligliptin 10 mg
Number of subjects: 99
Study 22776014 — intervention group
Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg
Number of subjects: 99
Study 22776014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 20057364 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass (GBP)
Number of subjects: 20
Study 20057364 — intervention group
Group type: COMPARATOR
Intervention: Gastric banding (GB)
Number of subjects: 20
Study 19033122 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy plus sodium glycididazole
Number of subjects: 60
Study 19033122 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy
Number of subjects: 60
Study 15867184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1441
Study 15867184 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 1441
Study 12557836 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ; 25 mg/kg)
Number of subjects: 198
Study 12557836 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP; 25 mg/kg of the sulfadoxine component)
Number of subjects: 198
Study 12557836 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ; 15 mg/kg)
Number of subjects: 198
Study 10376128 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 10376128 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 8866565 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of NIDDM (FH+)
Number of subjects: 2680
Study 8866565 — intervention group
Group type: EXPERIMENTAL
Intervention: Male offspring of diabetic mothers
Number of subjects: 2680
Study 8866565 — intervention group
Group type: EXPERIMENTAL
Intervention: Female offspring of diabetic mothers
Number of subjects: 2680
Study 1757038 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (initially 100 mg daily, reduction every 3 days)
Number of subjects: 38
Study 1757038 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B1 (100 mg thiamin daily)
Number of subjects: 38
Study 7041939 — intervention group
Group type: EXPERIMENTAL
Intervention: Three cycles of cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF)
Number of subjects: 112
Study 7041939 — intervention group
Group type: COMPARATOR
Intervention: Surgery or radiotherapy (after 3 cycles of CMF)
Number of subjects: 112
Study 7041939 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (CMF)
Number of subjects: 112
Study 7041939 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF treatment
Number of subjects: 112
Study 30370492 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg twice daily for 2 weeks
Number of subjects: 44
Study 30370492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 30370492 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 44
Study 30899947 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser combined with basic periodontal therapy
Number of subjects: 80
Study 30899947 — intervention group
Group type: COMPARATOR
Intervention: Basic periodontal therapy
Number of subjects: 80
Study 27593618 — intervention group
Group type: EXPERIMENTAL
Intervention: NO3‐ rich beetroot juice (4000 mg/L NO3‐)
Number of subjects: 46
Study 27593618 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 46
Study 24512799 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion
Number of subjects: 14
Study 22866961 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diets containing different levels of sucrose or high fructose corn syrup (HFCS)
Number of subjects: 0
Study 22866961 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise only group
Number of subjects: 0
Study 22866961 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 20354448 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathoracic blood volume index (ITBVI, n = 15)
Number of subjects: 30
Study 20354448 — intervention group
Group type: COMPARATOR
Intervention: Hourly urine output (HUO, n = 15)
Number of subjects: 30
Study 17452762 — intervention group
Group type: EXPERIMENTAL
Intervention: Cushing's syndrome patients
Number of subjects: 77
Study 17452762 — intervention group
Group type: COMPARATOR
Intervention: Age
Number of subjects: 77
Study 15494721 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pegylated liposomal doxorubicin (PLD) 45 mg m(‐2) and paclitaxel 150 mg m(‐2), every 28 days for a total of six cycles
Number of subjects: 42
Study 12467881 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine (FEX)
Number of subjects: 16
Study 12467881 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (CET)
Number of subjects: 16
Study 12467881 — intervention group
Group type: COMPARATOR
Intervention: Stanford Sleepiness Scale (SSS)
Number of subjects: 16
Study 12467881 — intervention group
Group type: COMPARATOR
Intervention: Psychomotor performance tests
Number of subjects: 16
Study 12467881 — intervention group
Group type: COMPARATOR
Intervention: PET with 11C-doxepin
Number of subjects: 16
Study 9892050 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimuli presentation
Number of subjects: 0
Study 9892050 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual response production
Number of subjects: 0
Study 9892050 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual addends in Arabic numerals
Number of subjects: 0
Study 9892050 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual addends
Number of subjects: 0
Study 7652069 — intervention group
Group type: EXPERIMENTAL
Intervention: Open release using a minimal incision
Number of subjects: 96
Study 7652069 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic carpal tunnel release
Number of subjects: 96
Study 7652069 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (open and endoscopic)
Number of subjects: 96
Study 2326093 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental pain sensitivity
Number of subjects: 44
Study 2326093 — intervention group
Group type: EXPERIMENTAL
Intervention: Position-dependent headache
Number of subjects: 44
Study 355585 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA (20 mg orally q 8 hr for 32 hr)
Number of subjects: 11
Study 355585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31356678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (KTZ) 200 or 400 mg
Number of subjects: 24
Study 31356678 — intervention group
Group type: COMPARATOR
Intervention: CYP3A5 expressers
Number of subjects: 24
Study 31451521 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent low-dose ASA (81 mg daily for one week/placebo for one week)
Number of subjects: 54
Study 31451521 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous low-dose ASA (81 mg daily)
Number of subjects: 54
Study 31451521 — intervention group
Group type: COMPARATOR
Intervention: Low-dose ASA (both intermittent and continuous)
Number of subjects: 54
Study 27768621 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological mesh closure
Number of subjects: 104
Study 27768621 — intervention group
Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 104
Study 26187121 — intervention group
Group type: EXPERIMENTAL
Intervention: Radically Open Dialectical Behaviour Therapy (RO-DBT) for 7 months (individual and group treatment)
Number of subjects: 0
Study 26187121 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 23948426 — intervention group
Group type: COMPARATOR
Intervention: Regular exercise group (core stability class including specific and global trunk exercises)
Number of subjects: 33
Study 23948426 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (regular exercises plus instruction on 8 specific stabilization muscles)
Number of subjects: 33
Study 23948426 — intervention group
Group type: COMPARATOR
Intervention: Regular exercise group
Number of subjects: 33
Study 23948426 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 33
Study 21500490 — intervention group
Group type: EXPERIMENTAL
Intervention: vitaprost plus in rectal suppositoria for 1 month, then vitaprost forte for 2 months
Number of subjects: 70
Study 21500490 — intervention group
Group type: COMPARATOR
Intervention: gentos and lomefloxacin per os
Number of subjects: 70
Study 19712593 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation (HBR)
Number of subjects: 89
Study 19712593 — intervention group
Group type: COMPARATOR
Intervention: Day hospital rehabilitation (DHR)
Number of subjects: 89